Current Trials

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).

Non-metastatic breast, colorectal, gastro-oesophagal or prostate cancer which can be treated and potentially cured.

The purpose of this study is to evaluate the the effects of aspirin on disease recurrence and survival in patients who have had primary curative therapy for common non-metastatic solid tumours.

Early stage breast cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab.

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

This study will asses the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM)

To determine the maximum tolerated dose (MTD), safety, and efficacy of afatinib monotherapy

Melanoma.

This study will evaluate the efficacy of NKTR-214 Combined with Nivolumab Versus Nivolumab

Melanoma.

The study will compare the pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C

Previously untreated or unresectable or Metastatic Melanoma

The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread.

Participants with Chronic Myeloid Leukaemia (CML) and Philadelphia-positive Acute Lymphoid Leukaemia (Ph+ALL) who are being treated with their first or subsequent tyrosine kinase inhibitor (TKI) therapy.

The purpose of this observational study is to evaluate the prevalence of mutations in patients with Chronic Myeloid Leukaemia (CML) who meet the European Leukaemia Net (ELN) criteria for warning or failure and patients with Philadelphia-positive Acute Lymphoid Leukaemia (Ph+ALL) with detectable BCR-ABL currently being treated with first or subsequent Tyrosine Kinase Inhibitor (TKI) therapy in the UK, Ireland, or France using Next-Generation Sequencing.

Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment.

The purpose of this study is to determine whether certain drug combinations are safe and effective.

Patients with cancer of the colon which has spread (metastasised).

The aim of the study is to identify and confirm one or more biomarkers (a biological substance) in blood and/or tissue, which will help us to identify the patients, who are going to respond to their treatment.

Multiple types of cancer.

This study will evaluate the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy

Advanced or recurrent endometrial carcinoma

This study will assess the anti-tumour activity of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK7902) Versus Chemotherapy for first line treatment.

Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis

This study will assess the efficacy and safety of fedratinib compared to best available therapy.

Bile duct cancer that is inoperable or has spread, in patients that test positive for FGFR2 gene fusion, or, FGFR2 gene mutations or amplifications.

To investigate the effects of the drug derazantinib (formerly ARQ 087) in patients who have a type of bile duct cancer that cannot be operated on, or has spread, called Advanced Intrahepatic Cholangiocarcinoma. Patients will have a positive genetic test for FGFR2 Gene Fusion or FGFR2 gene mutations or amplifications.